{"disease":{"id":"other-advanced-solid-tumors","name":"other advanced solid tumors"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06970795","title":"A Study of SYS6040 for Injection in Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"CSPC Megalith Biopharmaceutical Co.,Ltd.","has_results":false},{"nct_id":"NCT02073994","title":"Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":174,"lead_sponsor_name":"Institut de Recherches Internationales Servier","has_results":false},{"nct_id":"NCT07177937","title":"A Study of DXC014 in Patients With Advanced Solid Tumors.","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":150,"lead_sponsor_name":"Hangzhou DAC Biotechnology Co., Ltd.","has_results":false},{"nct_id":"NCT06191796","title":"Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":25,"lead_sponsor_name":"Exelixis","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}